Related Experiment Video
Updated: Aug 21, 2026

Synergizing Antegrade Endoscopic with Bridging Vein Harvesting for Improvement of Great Saphenous Vein Graft Quality from the Lower Leg
Published on: November 19, 2019
Cardiac saphenous vein bypass graft disease
G T Lau1, H C Lowe, L Kritharides
1Department of Cardiology, Concord Repatriation General Hospital, Hospital Rd, Concord, NSW 2139, Australia.
Insights
Coronary artery bypass grafting uses saphenous vein grafts, but graft disease causes occlusion. Research reviews graft disease mechanisms and highlights gene therapy
Area of Science:
- Cardiovascular Surgery
- Vascular Biology
- Regenerative Medicine
Background:
- Coronary artery bypass grafting (CABG) is crucial for myocardial ischemia, especially in multivessel disease and diabetes.
- Saphenous vein grafts (SVGs) have high occlusion rates (up to 40%) within 10 years.
- SVG disease involves thrombosis, intimal hyperplasia, and atherosclerosis.
Purpose of the Study:
- To review the pathology of saphenous vein graft disease.
- To examine key factors contributing to SVG disease, including nitric oxide, cellular proliferation, hypercholesterolemia, and hypertriglyceridemia.
- To highlight the potential of gene therapy for treating SVG disease.
Main Methods:
- Literature review of existing studies on saphenous vein graft disease.
- Analysis of pathological mechanisms including thrombosis, intimal hyperplasia, and atherosclerosis.
- Exploration of molecular and metabolic factors influencing graft failure.
Main Results:
- Saphenous vein graft disease is multifactorial, involving inflammatory and proliferative processes.
- Nitric oxide dysfunction, cellular proliferation, hypercholesterolemia, and hypertriglyceridemia are key contributors.
- Gene therapy has shown early promise in addressing SVG disease.
Conclusions:
- Understanding the mechanisms of SVG disease is critical for improving long-term graft patency.
- Novel therapeutic strategies, particularly gene therapy, offer significant potential for future treatments.
- Further research is needed to translate gene therapy benefits into clinical practice for CABG patients.
Abstract:
Coronary artery bypass grafting is an effective treatment for myocardial ischaemia and is particularly important in patients with multivessel disease and diabetes. However, up to 40% of saphenous vein grafts will occlude within 10 years of surgery. The predominant mechanisms for saphenous vein graft disease are thrombosis, intimal hyperplasia, and accelerated atherosclerosis. The pathology of these changes and the role of key factors such as nitric oxide, cellular proliferation, and the role of hypercholesterolemia and hypertriglyceridaemia, are reviewed. Saphenous vein graft disease is among the first cardiovascular conditions to show significant benefit from gene therapy and promises to show remarkable developments in the near future.
More Related Videos
Related Concept Videos
Peripheral Artery Disease V: Postoperative Nursing Management
Assessment of the Cardiovascular System III: Palpation
Jugular Venous Pressure (JVP) Measurement
Position the patient at a thirty- to forty-five-degree angle or in a semi-fowler's position. Look for the highest point of pulsation in the internal jugular vein and measure the vertical distance to the angle of Loius or sternal angle. A normal JVP is 3-4 cm above the...
Hemodialysis I: Introduction
Varicose Veins I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Varicose Veins II: Diagnostic Studies and Interprofessional Care

